High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids

Kirti K. Iyer, Henk M.W. Verheul(Erasmus MC)

Research Square

May 5, 2023

10.21203/rs.3.rs-2867114/v1

Cited by 3

Related Papers

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

|Angiogenesis|2009|488

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome

|Cancers|2020|18

SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma

|The Oncologist|2025|0